Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and... von Bonner, James A, Prof, Harari, Paul M, Prof, Giralt, Jordi, Prof, Cohen, Roger B, Prof, Jones, Christopher U, MD, Sur, Ranjan K, Prof, Raben, David, Prof, Baselga, Jose, Prof, Spencer, Sharon A, Prof, Zhu, Junming, PhD, Youssoufian, Hagop, MD, Rowinsky, Eric K, MD, Ang, K Kian, Prof

Volltext

Targeted Induction of Apoptosis in Cancer Management: The Emerging Role of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor Activating Agents von ROWINSKY, Eric K

Volltext

LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer von Tavazoie, Masoud F., Pollack, Ilana, Tanqueco, Raissa, Ostendorf, Benjamin N., Reis, Bernardo S., Gonsalves, Foster C., Kurth, Isabel, Andreu-Agullo, Celia, Derbyshire, Mark L., Posada, Jessica, Takeda, Shugaku, Tafreshian, Kimia N., Rowinsky, Eric, Szarek, Michael, Waltzman, Roger J., Mcmillan, Elizabeth A., Zhao, Connie, Mita, Monica, Mita, Alain, Chmielowski, Bartosz, Postow, Michael A., Ribas, Antoni, Mucida, Daniel, Tavazoie, Sohail F.

Volltext

Raf: A Strategic Target for Therapeutic Development Against Cancer von BEERAM, Muralidhar, PATNALK, Amita, ROWINSKY, Eric K

Volltext

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck von Bonner, James A, Harari, Paul M, Giralt, Jordi, Azarnia, Nozar, Shin, Dong M, Cohen, Roger B, Jones, Christopher U, Sur, Ranjan, Raben, David, Jassem, Jacek, Ove, Roger, Kies, Merrill S, Baselga, Jose, Youssoufian, Hagop, Amellal, Nadia, Rowinsky, Eric K, Ang, K. Kian

Volltext

The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors von Rowinsky, Eric K

Volltext

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2 von SPRATLIN, Jennifer L, COHEN, Roger B, MEROPOL, Neal J, LEWIS, Nancy L, CHIOREAN, E. Gabriela, FOX, Floyd, YOUSSOUFIAN, Hagop, ROWINSKY, Eric K, GAIL ECKHARDT, S, EADENS, Matthew, GORE, Lia, CAMIDGE, D. Ross, DIAB, Sami, LEONG, Stephen, O'BRYANT, Cindy, CHOW, Laura Q. M, SERKOVA, Natalie J

Volltext

A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction von Valle, Juan W., Armstrong, Anne, Newman, Chris, Alakhov, Valery, Pietrzynski, Grzegorz, Brewer, Julie, Campbell, Sue, Corrie, Pippa, Rowinsky, Eric K., Ranson, Malcolm

Volltext

Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer von PEREZ-SOLER, Roman, CHACHOUA, Abraham, HAMMOND, Lisa A, ROWINSKY, Eric K, HUBERMAN, Mark, KARP, Daniel, RIGAS, James, CLARK, Gary M, SANTABARBARA, Pedro, BONOMI, Philip

Volltext

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma von Rowinsky, Eric K., Paner, Agne, Berdeja, Jesus G., Paba-Prada, Claudia, Venugopal, Parameswaran, Porkka, Kimmo, Gullbo, Joachim, Linder, Stig, Loskog, Angelica, Richardson, Paul G., Landgren, Ola

Volltext

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors von MITA, Alain C, DENIS, Louis J, SEMIOND, Dorothée, BESENVAL, Michèle, TOLCHER, Anthony W, ROWINSKY, Eric K, DEBONO, Johann S, GOETZ, Andrew D, OCHOA, Leonel, FOROUZESH, Bahram, BEERAM, Muralidhar, PATNAIK, Amita, MOLPUS, Kathleen

Volltext

Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines von Lenz, Heinz-Josef, Van Cutsem, Eric, Khambata-Ford, Shirin, Mayer, Robert J, Gold, Philip, Stella, Philip, Mirtsching, Barry, Cohn, Allen L, Pippas, Andrew W, Azarnia, Nozar, Tsuchihashi, Zenta, Mauro, David J, Rowinsky, Eric K

Volltext

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients von Frankel, Arthur E., Woo, Jung H., Ahn, Chul, Pemmaraju, Naveen, Medeiros, Bruno C., Carraway, Hetty E., Frankfurt, Olga, Forman, Stephen J., Yang, Xuezhong A., Konopleva, Marina, Garnache-Ottou, Francine, Angelot-Delettre, Fanny, Brooks, Christopher, Szarek, Michael, Rowinsky, Eric

Volltext

In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent von Angelot-Delettre, Fanny, Roggy, Anne, Frankel, Arthur E, Lamarthee, Baptiste, Seilles, Estelle, Biichle, Sabeha, Royer, Bernard, Deconinck, Eric, Rowinsky, Eric K, Brooks, Christopher, Bardet, Valerie, Benet, Blandine, Bennani, Hind, Benseddik, Zehaira, Debliquis, Agathe, Lusina, Daniel, Roussel, Mikael, Solly, Françoise, Ticchioni, Michel, Saas, Philippe, Garnache-Ottou, Francine

Volltext

IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor von ROWINSKY, Eric K, YOUSSOUFIAN, Hagop, TONRA, James R, SOLOMON, Phillip, BURTRUM, Douglas, LUDWIG, Dale L

Volltext

Targeting the molecular target of rapamycin (mTOR) von Rowinsky, Eric K

Volltext

Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advance... von MITA, Monica M, MITA, Alain C, KNOWLES, Heather, RIVERA, Victor M, KREISBERG, Jeff, BEDROSIAN, Camille L, TOLCHER, Anthony W, CHU, Quincy S, ROWINSKY, Eric K, FETTERLY, Gerald J, GOLDSTON, Michelle, PATNAIK, Amita, MATHEWS, Lesley, RICART, Alejandro D, MAYS, Theresa

Volltext

LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a no... von Musher, Benjamin L, Rowinsky, Eric K, Smaglo, Brandon G, Abidi, Wasif, Othman, Mohamed, Patel, Kalpesh, Jawaid, Salmaan, Jing, James, Brisco, Amanda, Leen, Ann M, Wu, Mengfen, Sandin, Linda C, Wenthe, Jessica, Eriksson, Emma, Ullenhag, Gustav J, Grilley, Bambi, Leja-Jarblad, Justyna, Hilsenbeck, Susan G, Brenner, Malcolm K, Loskog, Angelica S I

Volltext

Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193) von SLEDGE, George W, NEUBERG, Donna, BERNARDO, Patricia, INGLE, James N, MARTINO, Silvana, ROWINSKY, Eric K, WOOD, William C

Volltext

A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer von HIDALGO, Manuel, BUCKNER, Jan C, ERLICHMAN, Charles, POLLACK, Marilyn S, BENI, Joseph P, DUKART, Gary, MARSHALL, Bonnie, SPEICHER, Lisa, MOORE, Laurence, ROWINSKY, Eric K

Volltext